Article: ABILIFY(R) (aripiprazole) Granted Approval for New Indication.

Efficacy Was Maintained With ABILIFY in Patients with Bipolar I Disorder With a Recent Manic or Mixed Episode Who Had Been Stabilized and Then Maintained for at Least Six Weeks

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) approved ABILIFY(R) (aripiprazole) Tablets and Oral Solution for maintaining efficacy in patients with Bipolar I Disorder with a recent manic or mixed episode who had been stabilized and then maintained for at least six weeks. The FDA approved ABILIFY for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder, ...

Related newspaper, magazine, and journal articles:

No articles like the one above were found.

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!